Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:37 PM
Ignite Modification Date:
2025-12-24 @ 4:37 PM
NCT ID:
NCT02097966
Eligibility Criteria:
This program is conducted in the EU (Germany, Austria, Norway, The Netherlands, Sweden and United Kingdom only)
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
* Patients chronically infected with Hepatitis C
* Patients at a high risk of liver decompensation or death within 12 months if left untreated and who have no available therapeutic options
Exclusion Criteria:
* Patients who are \<18 years old
* Patients who have contraindications to either Daclatasvir (DCV) or Sofosbuvir (SOF)
* Patients who are pregnant
* Creatinine clearance (CrCl) ≤ 30 mL/min (as estimated by Cockcroft and Gault formula)
* Patients who are pregnant or Women of Child Bearing Potential who are not using required contraception
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02097966
Study Brief:
Protocol Section:
NCT02097966